Key result
Aspirin reduced platelet COX-1-derived enzymatically oxygenated phospholipids while elevating diacyl 12-LOX-derived species in males, and P2Y12 inhibition reduced 12-LOX-derived species in leukocytes.
Why the study?
Enzymatically oxygenated phospholipids are pro-coagulant in model systems, but their generation in arterial thrombotic disease and modulation by common therapies is unknown.
Do common anti-platelet therapies (aspirin, P2Y12 inhibitors) modulate procoagulant enzymatically oxygenated phospholipids in arterial disease?
Population
Arterial vascular disease cohort, healthy cohort, retrieved human arterial thrombi, and mice lacking leukocyte 12/15-LOX
Comparison
Low dose aspirin or P2Y12 inhibition vs baseline or across cohorts
Design
Cohort and translational animal study
Authors
Loading...
First eoxPL characterization in arterial disease cohorts is hypothesis-generating; prospective studies needed before any clinical role.
Cohort (n=118)
Yes
Do common anti-platelet therapies (aspirin, P2Y12 inhibitors) modulate procoagulant enzymatically oxygenated phospholipids in arterial disease?
Common anti-platelet therapies like aspirin and P2Y12 inhibitors significantly alter the generation of pro-coagulant enzymatically oxygenated phospholipids, highlighting a novel mechanism that may influence thrombotic risk.
Protty et al. (2022) conducted a cohort in Arterial vascular disease (n=118). Aspirin and P2Y12 inhibitors vs. Healthy controls or pre-treatment baseline was evaluated on Levels of enzymatically oxygenated phospholipids (eoxPL). Aspirin reduced platelet COX-1-derived enzymatically oxygenated phospholipids while elevating diacyl 12-LOX-derived species in males, and P2Y12 inhibition reduced 12-LOX-derived species in leukocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: